Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients.

[1]  Andrea Cherrington,et al.  Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers , 2017, Clinical Diabetes.

[2]  Juan Li,et al.  The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. , 2014, Journal of diabetes and its complications.

[3]  T. Inoguchi,et al.  The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications , 2012, Diabetes & metabolism journal.

[4]  B. Shi,et al.  Changes to tear cytokines of type 2 diabetic patients with or without retinopathy , 2010, Molecular vision.

[5]  M. Lagarde,et al.  Increased Lipid Peroxidation in LDL from Type-2 Diabetic Patients , 2010, Lipids.

[6]  M. Rojas,et al.  Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study , 2010, BMC pulmonary medicine.

[7]  A. Esteghamati,et al.  Serum Oxidized-LDL is Associated with Diabetes Duration Independent of Maintaining Optimized Levels of LDL-Cholesterol , 2010, Lipids.

[8]  K. Pandey,et al.  Protein oxidation biomarkers in plasma of type 2 diabetic patients. , 2010, Clinical biochemistry.

[9]  C. Spadaccio,et al.  Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure , 2009, Diabetes/metabolism research and reviews.

[10]  S. Basu,et al.  Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects. , 2009, The British journal of nutrition.

[11]  V. Jakuš,et al.  HbA1c and Serum Levels of Advanced Glycation and Oxidation Protein Products in Poorly and Well Controlled Children and Adolescents with Type 1 Diabetes Mellitus , 2009, Journal of pediatric endocrinology & metabolism : JPEM.

[12]  A. Mooradian.  Dyslipidemia in type 2 diabetes mellitus , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[13]  B. Halliwell.  Oral inflammation and reactive species: a missed opportunity? , 2008, Oral diseases.

[14]  M. Spielmann,et al.  Enhanced susceptibility to infections in a diabetic wound healing model , 2008, BMC surgery.

[15]  T. Millar,et al.  ROS generation in endothelial hypoxia and reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil recruitment. , 2007, Free radical biology & medicine.

[16]  A. Luder,et al.  LDL oxidation is associated with increased blood hemoglobin A1c levels in diabetic patients. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[17]  I. Chapple,et al.  The role of reactive oxygen and antioxidant species in periodontal tissue destruction. , 2007, Periodontology 2000.

[18]  F. Nishimura,et al.  The periodontal host response with diabetes. , 2007, Periodontology 2000.

[19]  Greta L. Hoetzer,et al.  Influence of Metabolic Syndrome on Biomarkers of Oxidative Stress and Inflammation in Obese Adults , 2006, Obesity.

[20]  U. Çakatay.  Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. , 2005, Diabetes & metabolism.

[21]  B. Wisse,et al.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. , 2004, Journal of the American Society of Nephrology : JASN.

[22]  R. Krauss,et al.  Dyslipidemia in type 2 diabetes. , 2004, The Medical clinics of North America.

[23]  V. Trajković,et al.  Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. , 2004, Journal of autoimmunity.

[24]  Mitchell J. Anderson,et al.  Interleukin-6 and tumor necrosis factor-α are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness , 2004, Diabetologia.

[25]  R. Gambino,et al.  In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control. , 2004, Atherosclerosis.

[26]  F. Santilli,et al.  Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration , 2003, Circulation.

[27]  S. Haffner.  Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. , 2002, The American journal of cardiology.

[28]  R. Marfella,et al.  Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.

[29]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[30]  T. Lakka,et al.  Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. , 2001, Atherosclerosis.

[31]  S. Yeh,et al.  Total plasma malondialdehyde levels in 16 Taiwanese college students determined by various thiobarbituric acid tests and an improved high-performance liquid chromatography-based method. , 2000, Clinical biochemistry.

[32]  D. Strachan,et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. , 2000, European heart journal.

[33]  J. Peña,et al.  Enhanced Acute-Phase Response and Oxidative Stress in Older Adults with Type II Diabetes , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[34]  J. Pickup,et al.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. , 2000, Life sciences.

[35]  A. Hofman,et al.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[36]  R. Sundaram,et al.  Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. , 1996, Clinical science.

[37]  G. Paolisso,et al.  Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.

[38]  B. Bravenboer,et al.  The role of oxidative stress in neuropathy and other diabetic complications. , 1995, Diabetes/metabolism reviews.

[39]  M. Penn,et al.  Lipoprotein Oxidation and Lipoprotein-lnduced Cell Injury in Diabetes , 1992, Diabetes.

[40]  P. Winocour,et al.  Relation of Lipid Peroxides to Macrovascular Disease in Type 2 Diabetes , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[41]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[42]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[43]  K. Yagi,et al.  Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. , 1981, Biochemical medicine.

[44]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2015 .

[45]  Jennifer L. Gay,et al.  Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. , 2012, Cytokine.

[46]  E. Uskun,et al.  Periodontal status in subjects with hyperlipidemia. , 2009, Journal of periodontology.

[47]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[48]  D. Daleke,et al.  The role of oxidative stress in diabetic complications , 2007, Cell Biochemistry and Biophysics.

[49]  A. Vinik.  The metabolic basis of atherogenic dyslipidemia. , 2005, Clinical cornerstone.

[50]  U. Singh,et al.  Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. , 2005, Diabetes.

[51]  Nessar Ahmed,et al.  Advanced glycation endproducts--role in pathology of diabetic complications. , 2005, Diabetes research and clinical practice.

[52]  U. Singh,et al.  Hyperglycemia Induces Monocytic Release of Interleukin-6 via Induction of Protein Kinase C-α and -β , 2005 .

[53]  Z. Bloomgarden,et al.  Diabetes complications. , 2004, Diabetes care.

[54]  M. Taskinen.  Diabetic dyslipidemia. , 2002, Atherosclerosis. Supplements.

[55]  M. Pfeffer,et al.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. , 2000, Circulation.